Core Viewpoint - The company is undergoing a continuous innovation transformation, with multiple innovative pipelines being launched internationally, leading to an upward revision of revenue and profit forecasts for 2026 while maintaining profit forecasts for 2025 and 2027 [1] Group 1: Financial Analysis - The revenue projections for 2025, 2026, and 2027 are adjusted to 76.3 billion, 100.3 billion, and 110.4 billion respectively, up from previous estimates of 76.3 billion, 91.0 billion, and 110.4 billion [1] - The net profit attributable to the parent company for 2025, 2026, and 2027 is revised to 11.5 billion, 16.5 billion, and 16.6 billion respectively, compared to earlier estimates of 11.5 billion, 13.8 billion, and 16.6 billion [1] - The corresponding EPS for 2025, 2026, and 2027 is adjusted to 0.44, 0.64, and 0.64 respectively, up from previous estimates of 0.44, 0.53, and 0.64 [1] Group 2: Product Development - The company received a milestone payment of 40 million USD from AbbVie for SIM0500 on February 3, 2026, following a licensing agreement signed in January 2025 [1] - SIM0500 is a humanized TCE tri-antibody targeting two tumor-associated antigens, showing strong T-cell cytotoxic effects against multiple myeloma cells [2] - The FDA granted SIM0500 a fast track designation for use in patients with multiple myeloma who have received at least three prior lines of therapy and are resistant or intolerant to standard treatments [2] Group 3: Strategic Partnerships - Since 2025, the company has successfully licensed four pipelines internationally, including agreements with AbbVie, NextCure, Ipsen, and Boehringer Ingelheim, with potential total payments reaching up to 10.6 billion USD and 10.16 billion EUR [3] - The partnerships with major multinational corporations (MNCs) validate the company's enhanced innovation capabilities and suggest ongoing opportunities for new business development in the future [3]

Core Viewpoint - The company, Xiansheng Pharmaceutical (02096), is intensifying its innovative transformation with multiple innovative pipelines being launched internationally. The revenue and profit forecasts for 2026 have been raised due to the confirmation of upfront and milestone payments, while the 2025 and 2027 profit forecasts remain unchanged. The expected revenues for 2025-2027 are 7.63 billion, 10.03 billion, and 11.04 billion yuan respectively, with net profits of 1.15 billion, 1.65 billion, and 1.66 billion yuan, maintaining a "Buy" rating [1]. Business Analysis - On February 3, 2026, the company announced receiving a recent milestone payment of 40 million USD from AbbVie related to SIM0500 (GPRC5D/BCMA/CD3 tri-antibody). In January 2025, the company signed an overseas licensing option agreement with AbbVie for SIM0500, which includes an upfront payment and potential payments up to 1.055 billion USD, along with tiered royalties based on net sales outside Greater China [1][2]. - SIM0500 is a humanized TCE tri-antibody targeting two tumor-associated antigens, showing promising efficacy. It combines a low-affinity but highly targeted CD3 antibody with two anti-tumor-associated antibodies, GPRC5D and BCMA, demonstrating strong T-cell cytotoxic effects against multiple myeloma (MM) cells. In April 2024, SIM0500 received Fast Track designation from the FDA for patients with relapsed or refractory MM who have received at least three prior lines of therapy [1]. Innovation Transformation - Since 2025, the company has successfully licensed out four pipelines, including: 1. SIM0500 with AbbVie for licensing rights 2. SIM0505 (CDH6ADC) with NextCure, potentially yielding 745 million USD in related payments 3. SIM0613 (LRRC15ADC) with Ipsen, with a total transaction payment potential of 1.06 billion USD 4. SIM0709 (TL1A/IL-23 dual antibody) with Boehringer Ingelheim, which includes an upfront payment of 42 million euros and potential milestone payments up to 1.016 billion euros based on development progress and commercialization [2]. - The successful out-licensing of self-developed pipelines further validates the company's enhanced innovative R&D capabilities, with recognition from major multinational corporations (MNCs). There remains potential for continued new business development (BD) opportunities for numerous self-developed pipelines and innovative ADC platforms in the future [2].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [7]. Core Insights - The company has achieved significant business development (BD) progress, enhancing both the breadth and depth of its self-developed new drugs. Recent collaborations with major pharmaceutical companies indicate a strong pipeline and potential for revenue growth [4]. - The financial forecast predicts total revenue growth from 66.40 billion CNY in 2023 to 104.27 billion CNY by 2027, with a compound annual growth rate (CAGR) of approximately 16% [4][6]. - The net profit attributable to shareholders is expected to rise from 7.15 billion CNY in 2023 to 16.09 billion CNY in 2027, reflecting a significant increase in profitability [4][6]. Financial Summary - Revenue projections for the company are as follows: 6,640 million CNY in 2023, 6,635 million CNY in 2024, 7,690 million CNY in 2025, 9,009 million CNY in 2026, and 10,427 million CNY in 2027, with year-over-year growth rates of 4%, 0%, 16%, 17%, and 16% respectively [3][4]. - The net profit forecast shows a decline of 23% in 2023, followed by a recovery with growth rates of 3%, 63%, 16%, and 16% in the subsequent years [3][4]. - Earnings per share (EPS) are projected to increase from 0.28 CNY in 2023 to 0.62 CNY in 2027, indicating a positive trend in shareholder returns [3][4]. Business Development Highlights - The company has secured multiple partnerships, including a recent agreement with AbbVie for clinical development collaboration, which includes a payment of 40 million USD [4]. - A licensing agreement with Boehringer Ingelheim for a dual-specific antibody is expected to generate up to 1.016 billion EUR in milestone payments, showcasing the company's strong position in the market [4]. - The company is also advancing its ADC (antibody-drug conjugate) pipeline, with significant collaborations that enhance its competitive edge in the industry [4].

Core Insights - The collaboration between Sihuan Pharmaceutical and Boehringer Ingelheim aims to develop the dual-specific antibody SIM0709 for the treatment of inflammatory bowel disease (IBD) [2][3] - The agreement grants Boehringer Ingelheim global rights outside Greater China, with Sihuan Pharmaceutical receiving an upfront payment of €42 million and potential milestone payments up to €1.016 billion [2][4] - The partnership is expected to leverage Sihuan's innovative research capabilities and Boehringer Ingelheim's global development and commercialization strengths to accelerate the development of this innovative therapy [3][4] Company Developments - SIM0709 is developed from Sihuan's multi-antibody technology platform and targets two key pathways involved in IBD, showing superior efficacy in preclinical studies compared to existing therapies [3] - This collaboration marks Sihuan's second overseas licensing project in the autoimmune disease sector and the fifth self-developed innovative drug to be licensed out, with total potential transaction amounts exceeding $4.6 billion [4] - Sihuan has significantly increased its R&D investment, totaling approximately 9 billion RMB over the past five years, with the proportion of revenue from innovative drugs rising from 45% in 2020 to 77% in the first half of 2025 [4] Market Context - Over 3 million people globally are affected by IBD, highlighting a significant unmet clinical need in this therapeutic area [2] - The collaboration is positioned to redefine effective treatment methods and improve the quality of life for patients suffering from IBD [2][3]

Core Viewpoint - Xiansheng Pharmaceutical's subsidiary, Xiansheng Zaiming, has submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for research and development, team expansion, and business growth [2][4]. Group 1: Company Overview - Xiansheng Zaiming focuses on the research, development, and commercialization of innovative oncology drugs, having been established in December 2020 [4]. - The company has five commercialized products, including anti-angiogenesis drug Endu and PD-(L)1 inhibitor Envida, with over 15 products in its research pipeline [4]. Group 2: Financial Performance - Xiansheng Zaiming reported revenues of 1.522 billion yuan, 1.296 billion yuan, and 1.238 billion yuan for the first three quarters of 2023, 2024, and 2025, respectively, while incurring losses of 336 million yuan, 506 million yuan, and 303 million yuan during the same periods [4]. - Research and development expenses for the same periods were 831 million yuan, 708 million yuan, and 512 million yuan, with sales expenses of 626 million yuan, 629 million yuan, and 532 million yuan [5]. Group 3: Strategic Initiatives - The company aims to enhance financial flexibility and optimize cash flow through its independent listing, allowing both Xiansheng Pharmaceutical and Xiansheng Zaiming to access separate capital markets [4]. - Xiansheng Zaiming has entered into a global licensing agreement with Ipsen for the ADC SIM0613, potentially earning up to 1.06 billion USD in total payments, including milestone payments and royalties [6].

Core Insights - Zhou Yunshu, a former senior figure at Heng Rui Medicine, has been appointed as the president of Xiansheng Pharmaceutical, marking a significant leadership change in the industry [1][9][10] - The pharmaceutical industry is experiencing a wave of executive changes, reflecting a strategic adjustment among local companies to enhance their global competitiveness and innovation capabilities [1][10][17] Company Developments - Zhou Yunshu's new role at Xiansheng Pharmaceutical was highlighted during a strategic cooperation announcement with Jiangsu Provincial Tumor Hospital, although official confirmation of his appointment is still pending [1][10][14] - Xiansheng Pharmaceutical has shown strong growth, with a 15.14% increase in revenue to 3.585 billion yuan and a 32.2% rise in net profit to 604 million yuan in the first half of 2025 [3][12] - The company has expanded its innovative drug portfolio to 10 products, with innovative drug revenue reaching 2.776 billion yuan, accounting for 77.4% of total revenue [3][12] Industry Trends - The recent influx of executives with multinational backgrounds into local pharmaceutical companies is seen as a strategy to introduce advanced management systems and international operational models [1][10][17] - In 2025, the Chinese pharmaceutical industry reached a milestone with 76 approved innovative drugs and over 130 billion yuan in licensing transactions, indicating a significant shift in the industry landscape [17] - The competitive environment, characterized by intensified product competition and cost control pressures, is driving local companies to adapt and innovate [17]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Simcere Zaiming Pharmaceutical Co., Ltd. 先聲再明醫藥股份有限公司 (A joint stock company with limited liability incorporated in ...

Core Viewpoint - The Hong Kong Stock Connect innovative drug ETF managed by E Fund (159316) has shown a strong rebound, rising over 4.5% in early trading, indicating positive market sentiment towards innovative drug development in China [1] Group 1: Innovative Drug Development - Innovent Biologics' anti-CTLA-4 monoclonal antibody "Daboshu" has been approved as the first domestic drug of its kind, filling a gap in the market [1] - The TROP2 ADC "Dercumab" jointly developed by AstraZeneca and Daiichi Sankyo has been approved for breast cancer indications in China, strengthening the ADC sector [1] Group 2: Business Development (BD) Growth - By December 31, 2025, the total transaction amount for China's innovative drug BD overseas licensing is expected to reach $135.655 billion, with upfront payments of $7 billion and a total of 157 transactions, marking historical highs across various metrics [1] - Recent BD transactions include: - Tongyi Medicine's peptide-conjugated drug CBP-1018 for prostate cancer licensed to MultiValent Biotherapies for $2 billion [1] - Ascletis Pharma's ADC drug SIM0613 licensed to Ipsen for $1.06 billion [1] - GRAIL's pan-KRAS inhibitor entering a Co-Co collaboration with AstraZeneca for over $2 billion, setting a record for clinical-stage small molecule collaborations [1] Group 3: Key Products - E Fund's Hong Kong Stock Connect innovative drug ETF (159316, linked A/C: 024328/024329) [1] - E Fund's Hong Kong Stock Connect pharmaceutical ETF (513200, linked A/C: 018557/018558) [1] - E Fund's Hang Seng Biotechnology ETF (159105) [1]

Investment Rating - The report does not explicitly state an investment rating for the biopharmaceutical industry, but it suggests a positive outlook based on upcoming catalysts and potential drug approvals. Core Insights - The biopharmaceutical sector is expected to see significant developments in 2026, with multiple domestic drugs anticipated to report key clinical data. This includes drugs from companies like Betta Pharmaceuticals, Hutchison China MediTech, and CanSino Biologics, which are expected to read out critical clinical data in 2026 [3][21]. - The report emphasizes that the long-term theme for the innovative drug sector is international expansion, with several sub-themes to focus on, including overseas business development (BD) licensing, key clinical trials, and unexpected overseas sales growth [3][18]. Summary by Sections Weekly New Drug Market Review - From December 22 to December 28, 2025, the top five gainers in the new drug sector were Dongyao Pharmaceutical (+23.15%), Beihai Kangcheng (+19.27%), Junshengtai (+16.41%), Shiyao Group (+6.95%), and Ailis (+5.78%). The top five losers were Gakos (-16.11%), Jiahe Biotech (-10.29%), Laika Pharmaceuticals (-9.33%), Yunding Xinyao (-8.98%), and Yongtai Biotech (-6.94%) [1][14]. Weekly Focused Stocks - The report suggests focusing on several stocks with high overseas expansion potential, including: 1. Companies with MNC certification and high overseas volume certainty: Sanofi, United Pharmaceuticals, and Kelun-Biotech. 2. Companies with overseas data catalysts: Betta Pharmaceuticals, Hutchison China MediTech, and InnoCare Pharma. 3. Potential heavyweights for overseas MNC licensing: Junshi Biosciences, Shiyao Group, and Yifang Biotech. 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat loss and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2][18]. Weekly New Drug Approval & Acceptance Status - This week, 23 new drug or new indication applications were approved in China, and 10 new drug or new indication applications were accepted [4][19]. Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 99 new drug clinical applications were approved, and 64 new drug clinical applications were accepted [5][24]. Key Domestic Market Events - Notable events include: 1. Xiansheng Zhaoming announced a global exclusive licensing agreement with Ipsen for an ADC drug, potentially worth up to $1.06 billion. 2. He Yu Pharmaceuticals received approval for its CSF-1R selective small molecule inhibitor. 3. Tongyi Pharmaceuticals announced a licensing agreement for a peptide conjugate drug for prostate cancer, with potential payments totaling around $2 billion [10]. Key Overseas Market Events - Significant overseas events include: 1. Novo Nordisk received FDA approval for a 25mg oral semaglutide tablet for weight loss. 2. Sanofi announced a cash acquisition agreement for Dynavax Technologies Corporation, valued at approximately $2.2 billion. 3. Agios Pharmaceuticals announced FDA approval for an oral PK activator for treating α or β thalassemia in adult patients [11].

Core Viewpoint - The company has entered a significant phase of monetization with its innovative drug pipeline, as evidenced by the recent licensing agreement for SIM0613 with Ipsen for $45 million upfront and a total of $1.06 billion, indicating a trend towards external licensing of its products [1][2]. Group 1: Product Development and Licensing - The licensing of SIM0613 marks the company's third external authorization project in 2025, confirming the advancement of its innovative drug pipeline [1]. - SIM0613 has shown advantages in preclinical models, particularly in osteosarcoma and triple-negative breast cancer, positioning it as a potential first-in-class (FIC) therapy globally [2]. - The ADC platform's capabilities are further validated with the second transaction involving SIM0613, following SIM0505, which is currently in Phase I clinical trials [2]. Group 2: Global Pipeline Expansion - The company is accelerating its global pipeline expansion, with multiple products and technology platforms poised for overseas exploration, including SIM0709, a dual antibody with significant global competitiveness [2]. - Clinical results for SIM0237 have been disclosed, showing promising outcomes in bladder cancer patients, indicating the potential for further development [2]. - The company is rapidly advancing its global clinical trials, with SIM0500 in Phase I and SIM0278 in Phase II, demonstrating effective collaboration with partners [2]. Group 3: New Product Contributions to Growth - New products are becoming a strong driver for future growth, particularly in the CNS field with the launch of a non-addictive insomnia treatment, which has quickly gained traction since its release [3]. - The oncology sector is also benefiting from the potential of oral SERDs, with ongoing Phase III trials validating the market opportunity [3]. - In the infection and autoimmune sectors, new products are expected to receive regulatory approval by 2026, further enhancing the company's growth prospects [3]. Group 4: Financial Projections and Valuation - The company maintains its adjusted net profit forecasts for 2025-2027 at 1.18 billion, 1.40 billion, and 1.52 billion yuan, respectively, with a CAGR of 14% [3]. - The target price has been adjusted to 19.82 HKD based on a PE valuation method, reflecting a shift in market expectations for comparable companies [3].